Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [
Animals
Brain Neoplasms
/ diagnostic imaging
CD8 Antigens
/ immunology
CD8-Positive T-Lymphocytes
/ metabolism
Copper Radioisotopes
Female
Glioblastoma
/ diagnostic imaging
Heterocyclic Compounds, 1-Ring
/ pharmacokinetics
Humans
Isotope Labeling
Lymphocytes, Tumor-Infiltrating
/ metabolism
Mice
Positron-Emission Tomography
/ methods
Radiopharmaceuticals
/ pharmacokinetics
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
received:
17
08
2020
revised:
15
12
2020
accepted:
15
01
2021
pubmed:
27
1
2021
medline:
11
3
2022
entrez:
26
1
2021
Statut:
ppublish
Résumé
Glioblastoma (GBM) is the most common malignant brain tumor in adults. Various immunotherapeutic approaches to improve patient survival are being developed, but the molecular mechanisms of immunotherapy resistance are currently unknown. Here, we explored the ability of a humanized radiolabeled CD8-targeted minibody to noninvasively quantify tumor-infiltrating CD8-positive (CD8 We generated a peripheral blood mononuclear cell (PBMC) humanized immune system (HIS) mouse model and quantified the absolute number of CD8 Nontumor-bearing NOG mice injected with human PBMCs showed prominent [ Human CD8
Identifiants
pubmed: 33495310
pii: 1078-0432.CCR-20-3243
doi: 10.1158/1078-0432.CCR-20-3243
pmc: PMC8026513
mid: NIHMS1666782
doi:
Substances chimiques
CD8 Antigens
0
Copper Radioisotopes
0
Copper-64
0
Heterocyclic Compounds, 1-Ring
0
Radiopharmaceuticals
0
1,4,7-triazacyclononane-N,N',N''-triacetic acid
56491-86-2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1958-1966Subventions
Organisme : NIGMS NIH HHS
ID : T32 GM073546
Pays : United States
Organisme : NIH HHS
ID : S10 OD023669
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA232130
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA210100
Pays : United States
Organisme : NINDS NIH HHS
ID : R35 NS105109
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009512
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Nat Neurosci. 2018 Oct;21(10):1380-1391
pubmed: 30224810
Nucl Med Biol. 2019 Apr;71:32-38
pubmed: 31128476
Nat Med. 2019 Mar;25(3):470-476
pubmed: 30742120
Nature. 2020 Jan;577(7792):689-694
pubmed: 31942068
Annu Rev Pathol. 2017 Jan 24;12:187-215
pubmed: 27959627
Sci Transl Med. 2017 Jul 19;9(399):
pubmed: 28724573
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1108-13
pubmed: 24390540
Nat Med. 2018 Sep;24(9):1459-1468
pubmed: 30104766
Semin Neurol. 2018 Feb;38(1):62-72
pubmed: 29548053
Cancer Res. 2016 Jan 1;76(1):73-82
pubmed: 26573799
N Engl J Med. 2016 Dec 29;375(26):2561-9
pubmed: 28029927
Br J Cancer. 2011 Jun 28;105(1):93-103
pubmed: 21629244
J Vis Exp. 2018 Jun 14;(136):
pubmed: 29985311
Nature. 2019 Jan;565(7738):234-239
pubmed: 30568305
Trends Immunol. 2018 Sep;39(9):748-763
pubmed: 30077656
Cancer Res. 2020 Jul 1;80(13):2903-2913
pubmed: 32409308
Nat Med. 2019 Mar;25(3):477-486
pubmed: 30742122
Clin Cancer Res. 2017 Jan 1;23(1):149-158
pubmed: 27458246
Lancet Oncol. 2020 May;21(5):655-663
pubmed: 32251621
J Clin Oncol. 2012 Nov 1;30(31):3884-92
pubmed: 22987087
Neuro Oncol. 2020 Aug 17;22(8):1073-1113
pubmed: 32328653
J Infect Dis. 2013 Nov;208 Suppl 2:S125-30
pubmed: 24151318
J Nucl Med. 2020 Apr;61(4):512-519
pubmed: 31586002
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
J Transl Med. 2014 Apr 29;12:107
pubmed: 24779345
Neurooncol Adv. 2019 May 28;1(1):vdz010
pubmed: 32642650
N Engl J Med. 2018 Aug 23;379(8):722-730
pubmed: 30134131
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821